Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS-IGAN: OMS721 in IgA nephropathy
2018-000075-33Phase 3Terminated
- Sponsor
- Omeros Corporation
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing OMS721 with Placebo (2 arms). Primary endpoint: Change from baseline in 24-hour urine protein excretion at 24 weeks. Started Mar 2018; status: terminated.
02
Drugs
narsoplimab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2018-000075-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000075-33.